Table 1 Transition probabilities
From: Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain
| From: | MAW | HTP | LITP | |
|---|---|---|---|---|
| To: | Methadone | B/N | ||
| MAW | 50.0% | 5.0% | 18.0% | 0.0% |
| HTP | 35.0% | 75.0% | 63.0% | 5.0% |
| LITP | 15.0% | 20.0% | 19.0% | 95.0% |
From: Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain
| From: | MAW | HTP | LITP | |
|---|---|---|---|---|
| To: | Methadone | B/N | ||
| MAW | 50.0% | 5.0% | 18.0% | 0.0% |
| HTP | 35.0% | 75.0% | 63.0% | 5.0% |
| LITP | 15.0% | 20.0% | 19.0% | 95.0% |